Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

40 results about "Angiogenesis Factor" patented technology

Angiogenic factor. Any of a group of substances present in the circulation (most of which are polypeptides—e.g., angiogenin, fibroblast growth factor, transforming growth factors and some lipids) which play a role in blood vessel formation. Angiogenic factors are increased after myocardial ischaemia.

Two-phase hydrogel system based on space-time gradient regulation and control as well as preparation method and application of two-phase hydrogel system

PendingCN120346382AMicrocapsulesProsthesisVascularizesVascularized bone
The invention relates to a two-phase hydrogel system based on space-time gradient regulation and control as well as a preparation method and application of the two-phase hydrogel system. The biphase hydrogel system can also be expressed as a GelMA composite hydrogel scaffold of a porous structure, the whole biphase hydrogel system is of a core-shell structure, the inner layer core mineralizes SilMA hydrogel microspheres, the porous GelMA hydrogel scaffold is used as an outer layer, and the angiogenesis promoting factor dimethyl oxalaminoacetic acid, the human umbilical vein endothelial cells and the bone marrow mesenchymal stem cells are loaded on the outer layer. Wherein the inner-layer core mineralized SilMA hydrogel microspheres realize continuous release of osteogenesis signals by slowly releasing nHAp, and the outer-layer porous GelMA hydrogel stent releases DMOG by rapid degradation to realize early angiogenesis, so that space-time coupling construction of blood vessels and bone tissues is realized. Through differential degradation characteristics of inner and outer layers of hydrogel, precise time sequence cooperative regulation and control of angiogenesis and bone tissue remodeling can be realized, and the bionic property and function integration capability of a vascularized bone organ structure can be improved, so that the clinical transformation potential of the vascularized bone organ structure is improved.
Owner:SHANGHAI UNIV +2

Combination treatment

PCT designated stageWO2025219562A1Senses disorderAntipyreticDiseaseAngiogenesis Factor
The present disclosure provides the medical use of an antigen-binding molecule that binds to gp130 in combination with an antagonist of an angiogenic factor to treat / prevent fibrosis, diseases / conditions characterised by fibrosis, pathological angiogenesis, diseases / conditions characterised by angiogenesis, pathological inflammation and / or diseases / conditions characterised by inflammation. The present disclosure also provides a combination comprising an antigen-binding molecule that binds to gp130 and an antagonist of an angiogenic factor.
Owner:VVB BIO PTE LTD +1

Black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as preparation method and application of black phosphorus hydrogel microneedle patch

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.
Owner:NANJING DRUM TOWER HOSPITAL

Application of fructus amomi volatile oil and / or bornyl acetate in preparation of medicine for preventing and / or treating preeclampsia

PendingCN118924856Agood treatment effectrepair structureAntipyreticDigestive systemPLACENTAL FUNCTIONSPharmaceutical Substances
The invention discloses application of fructus amomi volatile oil and / or bornyl acetate in preparation of a medicine for preventing and / or treating preeclampsia. The invention also discloses application of fructus amomi volatile oil and / or bornyl acetate in preparation of a medicine for preventing and / or treating hypertension caused by preeclampsia, or a medicine for preventing and / or treating proteinuria caused by preeclampsia, or a medicine for reversing placenta weight reduction caused by preeclampsia. The invention relates to a medicine for recovering fetal intrauterine growth limitation caused by preeclampsia, a medicine for recovering placenta tissue pathological damage or placenta dysfunction caused by preeclampsia, a medicine for recovering angiogenesis and anti-angiogenesis factor imbalance caused by preeclampsia, or a medicine for relieving colitis caused by preeclampsia, or a medicine for recovering fetal intrauterine growth limitation caused by preeclampsia, or a medicine for recovering placenta tissue pathological damage or placenta dysfunction caused by preeclampsia. The invention also relates to application of the traditional Chinese medicine composition in medicines for repairing colon barrier injury or intestinal permeability increase caused by preeclampsia. The traditional Chinese medicine composition overcomes the limitations of single effect and adverse reaction of gastrointestinal tracts in the current preeclampsia treatment medicine.
Owner:SOUTHERN MEDICAL UNIVERSITY

A sustained-release liposome for treating choroidal neovascularization of fundus and its preparation method and application

The present application relates to the technical field of nanomedicine delivery system, and particularly relates to a slow-release liposome for treating choroidal neovascularization of fundus, a preparation method and application thereof. The slow-release liposome for treating choroidal neovascularization of fundus comprises a liposome shell loaded with brivanib and liquid fluorocarbon, and a cell penetrating peptide and an anti-CD105 antibody are connected to the liposome shell. The present application selects a double-target drug brivanib, and prepares a novel nanoparticle modified by a cell penetrating peptide and targeted to vascular endothelial cells. The nanoparticle can penetrate the blood-ocular barrier and the cell membrane into the cell interior under the mediation of the cell penetrating peptide, so that persistent, efficient and precise treatment of choroidal neovascularization is realized. The technical scheme can solve the technical problem that the prior art lacks a drug delivery system capable of simultaneously realizing long-acting release, breaking through multiple barriers in the eye and synergistically inhibiting multiple target pro-angiogenic factors, and has an ideal application and promotion prospect.
Owner:THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV

Method for retaining a subperiosteal implant at the base of the alar wings

PendingCN122624221AAchieve mechanical anchoringReduced risk of displacementVascularizesImmunomodulating Agent
The present application relates to a kind of nasal ala base subperiosteal implant retention method, belong to plastic surgery medical instrument technical field.The present application provides a kind of nasal ala base subperiosteal implant soft tissue suspension retention method and its implant and system.The method includes: implant is placed into maxillary bone subperiosteal interstice, and implant fixed wing is fixed with the soft tissue anchor point such as alar base ligament of alar elevating lip muscle using drug-loaded degradable suture and is suspended and fixed.Implant surface is provided with the microporous structure of guiding tissue ingrowth, and is provided with the drug depot recess of filling load immunomodulator temperature-sensitive hydrogel.Postoperative healing process, suture is released under the action of tension to accelerate proangiogenic factor and promote local vascularization, and temperature-sensitive hydrogel slow-release immunomodulator induces macrophage to repair type polarization, and cooperatively promotes the biological chimeric fixation of implant and soft tissue.The present application can realize the double stable retention of implant, reduces postoperative displacement risk.
Owner:SHANGHAI YUEYAN MEDICAL BEAUTY CLINIC CO LTD

Vascularization-promoting allogeneic nerve repair material and preparation method thereof

The invention discloses a method for promoting vascularization of an allogeneic nerve repair material, and belongs to the field of peripheral nerve repair materials. The vascularization-promoting allogeneic nerve repair material is based on an acellular allogeneic nerve, and an astragalus polysaccharide alginic acid sustained-release microcapsule is compounded on the surface of the acellular allogeneic nerve. The decellularized allogeneic nerve is degreased and decellularized in a physical mode, and antigen components are effectively removed; the astragalus polysaccharide is a natural extract from tonifying traditional Chinese medicine astragalus, and compared with an angiogenesis factor, the astragalus polysaccharide has the advantages of no tumorigenicity, stable activity, low price and the like. The vascularization-promoting allogeneic nerve repair material disclosed by the invention can solve the problem of insufficient cell and nutrition supply caused by slow vascularization after allogeneic nerve implantation, and promotes nerve repair.
Owner:SHANXI ORUI BIOMATERIALS CO LTD

Bone tissue repair material for promoting vascularization and new bone formation and preparation method thereof

The invention belongs to the technical field of biomedical materials, and discloses a bone tissue repair material for promoting vascularization and new bone generation and a preparation method thereof. The bone tissue repair material is composed of a decalcified bone matrix and a degradable biological source gel material. The repair material has a loose porous three-dimensional structure similar to that of natural cancellous bone, and the temperature-sensitive gel material filled in the pore structure of the repair material can form gel in situ in vivo and is attached to pores of a decalcified bone matrix, so that cell migration, adhesion and proliferation can be promoted, the degradation rate of gel in vivo can be reduced, and the repair material has a good application prospect. The continuous release of the pro-angiogenesis factor is ensured. Good biocompatibility is achieved, and cytotoxicity and immunogenicity are avoided; meanwhile, in the slow degradation process, angiogenesis promoting factors are continuously released for a long time, and angiogenesis and new bone generation are promoted. Therefore, the implanted biological scaffold prepared from the bone tissue repair material has excellent bone repair and regeneration promotion capability and wide application prospect.
Owner:ARMY MEDICAL UNIV

Multispecific fusion proteins targeting angiogenic and inflammatory factors

This invention provides an antibody fusion protein comprising a binding construct that targets and is capable of binding to Ang-2, IL-6 receptors, and at least one VEGF family member; or an antigen-binding fragment or domain of the antibody fusion protein. The antibody fusion protein comprises an antibody or binding peptide against Ang-2, an antibody against IL-6R, and multiple extracellular domains of the VEGF receptor as binding components. The antibody fusion protein is suitable for treating or controlling ocular or systemic diseases, symptoms, or conditions caused by abnormal angiogenesis, increased vascular leakage, or inflammation.
Owner:F HOFFMANN LA ROCHE & CO AG

Stem cell exosome composition and application thereof in treating diabetic complications

The invention discloses a targeting stem cell exosome composition and application thereof in treating diabetic foot ulcer. According to the composition, a mesenchymal stem cell exosome is modified through genetic engineering, specific targeting fusion polypeptide is expressed on the surface of the mesenchymal stem cell exosome, anti-inflammatory miR-146a and a pro-angiogenic factor VEGF are loaded, and then the mesenchymal stem cell exosome is compounded with temperature-sensitive hyaluronic acid hydrogel to form a sustained release system. The sequence of the fusion polypeptide is as shown in SEQ ID NO: 1, and the targeting of exosomes to diabetic inflammation parts is remarkably improved; the stability of miR-146a is enhanced through chemical modification, and the miR-146a cooperates with VEGF to inhibit inflammation and promote revascularization. In-vitro experiments show that the composition reduces the levels of TNF-alpha and IL-6 by 85% and 88% respectively, and the cell migration rate reaches 99.3%; in-vivo experiments show that the wound healing rate of diabetic rats reaches 99.6% on the 14th day, and the collagen deposition area proportion is increased to 77.5%. The invention has targeting property, function synergy and slow release performance, and provides an efficient treatment strategy for diabetic foot ulcer.
Owner:GUANGDONG FENGTAI BIOMEDICAL TECHNOLOGY CO LTD

Biologic composition for promoting wound healing and a method of preparing the same

A biologic composition for promoting wound healing includes: a human mesenchymal stem cell (MSC)-derived extracellular matrix (ECM) biologic component, and a negatively charged polymer, combined with the biologic component to form the biologic composition. A method of preparing the biologic composition thereof includes: (i) isolating human mesenchymal stem cells (MSC) and subjecting the MSC to hypoxia-priming in a xeno- and / or serum-free, or chemically defined medium to stimulate the production of an MSC-derived biologic component with pro-angiogenic factors; (ii) aggregating and co-precipitating the MSC-derived biologic component with a negatively charged polymer into a pericellular space of the MSC to produce an aggregated biologic component; (iii) assembling the aggregated biologic component and the negatively charged polymer into an insoluble extracellular matrix (ECM) by the MSC; and (iv) decellularizing the insoluble ECM to obtain the biologic composition comprising MicroParticles of Solidified Secretome (MIPSOS).
Owner:CENTER FOR NEUROMUSCULOSKELETAL RESTORATIVE MEDICINE LIMITED

Piezoelectric stimulation and AVT coupled coaxial electrostatic spinning stent, preparation and application in mandible defect vascularized bone regeneration

The invention discloses a novel coaxial electrostatic spinning stent coupling piezoelectric stimulation and AVT, the morphology of the stent simulates an extracellular matrix, adhesion, growth and differentiation of cells are facilitated, and a space is provided for growth of new blood vessels and new bones; the coaxial electrostatic spinning stent takes an artificial high polymer material as a matrix, is good in biological safety and can be degraded in vivo, and a degradation product is non-toxic; a clinical drug AVT for promoting angiogenesis is loaded in a fiber shell layer, and the defects that various angiogenesis promoting factors are high in price, short in half-life period, insufficient in potential safety and the like are overcome; the piezoelectric material ZnO for promoting osteogenic differentiation is loaded on the fiber core layer, various defects of external electrical stimulation equipment are avoided, the osteogenic differentiation is continuously promoted by collecting masticatory muscle force and converting the masticatory muscle force into piezoelectric stimulation, meanwhile, angiogenesis is promoted in combination with early release of AVT, and finally, vascularized bone regeneration of lower jawbone defects is promoted. According to the invention, the source of required materials is sufficient, the preparation technology is simple, the cost is low, the biological safety is good, and the potential clinical application prospect is achieved.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Improved stem cell composition

To solve the problem in which the use of stem cells alone to promote angiogenesis remains limited because of insufficient expression of angiogenic factors in many types of stem cells.SOLUTION: The disclosure provides stem cells which express high levels of Angiopoietin-1 (Ang1) and methods for their production. Such stem cells may be used in a wide range of therapeutic applications.SELECTED DRAWING: None
Owner:MESOBLAST INTERNATIONAL SARL

Use of ingenol HEP14 in preparation of drug, dosage form of HEP14-based drug, and preparation method for dosage form

PCT designated stageWO2025260453A1Organic active ingredientsAntinoxious agentsGranular leucocyteGranulosa cell
A novel medical use of ingenol HEP14, a dosage form of an HEP14-based drug, and a preparation method for the dosage form. The dosage form of the HEP14-based drug is an HEP14 / PLGA microsphere sustained-release dosage form formed by encapsulating the HEP14-based drug with a polylactic acid-glycolic acid copolymer, and has the functions of high HEP14 drug loading rate, high encapsulation rate, and long-acting HEP14 sustained-release. It has been found for the first time that HEP14 can promote production and autophagy of mitochondria in cells and enhance the function of mitochondria in cells, promote the secretion of antioxidant enzymes and remove reactive oxygen species, promote the growth and viability of ovarian follicle granulosa cells and restore the growth and viability of aging granules, promote the secretion of angiogenic factors, reduce the fibrosis of ovarian tissues, promote the angiogenesis of ovarian tissues, and promote the regeneration of aged ovarian follicles and ovarian endocrine functions, and thus has a good effect of treating and / or preventing related diseases caused by mitochondrial dysfunction, especially the effect of treating age-related ovarian decline.
Owner:BLOOM BIOTECHNOLOGY CO LTD (SHENZHEN)

Fusion proteins for inhibiting angiogenesis

The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
Owner:ALLGENESIS BIOTHERAPEUTICS INC

GelMA hydrogel loaded with acellular fat extract and flap survival application

PendingCN121731547AProsthesisTube formationCell free
The invention discloses cell-free fat extract loaded GelMA hydrogel and skin flap survival application, and particularly relates to the technical field of biomedical engineering. The hydrogel is prepared from GelMA, Ceffe, lithium phenyl (2, 4, 6-trimethylbenzoyl) phosphonate and a phosphate buffer salt solution. Wherein the Ceffe is rich in a plurality of angiogenesis promoting factors and is obtained through physical emulsification and centrifugal extraction; gelMA is prepared by modifying pig A-type gelatin through methacrylic anhydride, and has temperature-sensitive and photo-crosslinking characteristics. The injectable hydrogel with a porous network structure is formed by mixing Ceffe and a GelMA solution and curing through ultraviolet irradiation. The compound system realizes Ceffe biphasic slow release, remarkably promotes proliferation, migration and tube formation of vascular endothelial cells in vivo and in vitro, improves the survival rate of random skin flaps of mice, and effectively relieves oxidative stress injury caused by ischemia reperfusion by up-regulating HO-1 and down-regulating INOS.
Owner:AFFILIATED PEOPLES HOSPITAL OF NINGBO UNIV

Compositions and methods for improving vision

PendingUS20260007686A1Organic active ingredientsSenses disorderNear visual acuityControlled release
Implants comprising steroid dimers for use in improving vision and treating ocular disorders and conditions are provided. Said steroid dimers have the structure D1-L-D2 with D1 and D2 preferably being dexamethasone with the dexamethasone radicals linked by a hydrolyzable linker L. The implants provide for a controlled release of the dexamethasone with any treatment potentially involving the use of multiple implants intravitreally administered no less than 1 month, preferably no less than 3 months after intravitreally administration of the prior implant. The implants may also be used in conjunction with other therapeutic agents including anti-inflammatory or angiogenesis factors. These implants have utility in improving visual acuity, treating vision deterioration and treating ocular disorders and conditions, in particular by decreasing central subfield thickness.
Owner:RIPPLE THERAPEUTICS CORP

Administration of an anti-activin-a compound to a subject

The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
Owner:ATARA BIOTHERAPEUTICS INC +1

PEDF mutant targeting VEGFR2 (vascular endothelial growth factor receptor 2) and application of PEDF mutant

PendingCN120518748ASenses disorderPeptide/protein ingredientsIschemic retinopathyDisease
The invention relates to the technical field of biology, in particular to a PEDF mutant targeting VEGFR2 (vascular endothelial growth factor receptor 2) and application of the PEDF mutant in fundus neovascularization diseases. The sequence of the PEDF mutant of the targeted VEGFR2 is as shown in SEQ ID NO: 1. The invention provides a single injection recombinant adeno-associated virus (rAAV) gene therapy, which is used for treating VEGF (vascular endothelial growth factor) related eye diseases. The therapy prevents neovascularization by inducing expression of a mutant pigment epithelium-derived factor (PEDF). The method comprises the following steps: firstly, establishing two animal models of fundus neovascularization diseases, namely an extremely low density lipoprotein receptor gene knockout (Vldlr <- / ->) mouse model and an oxygen-induced ischemic retinopathy (OIR) mouse model; subsequently, anti-angiogenesis factors are injected into a vitreous cavity, and the result shows that clinically remarkable vasculopathy is almost completely inhibited in the established mouse fundus neovascularization model.
Owner:XIAMEN SHUOWANG PHARM TECH CO LTD

Application of antisense nucleotide for inhibiting NEAT1 in treatment, improvement or prevention of fundus neovascularization in targeted parasite assembly domain

PendingCN121714598AOrganic active ingredientsSenses disorderOcular neovascularizationNucleotide
The invention discloses application of antisense nucleotide for inhibiting NEAT1 in a targeted parasite assembly domain to treatment, improvement or prevention of fundus neovascularization, and belongs to the technical field of biological medicine. The invention finds that NEAT1 and downstream pro-angiogenesis factors CYR61 and FGF2 are obviously up-regulated in wet age-related macular degeneration patients and CNV model mice. According to the invention, the NEAT1 in the retina and the choroid is efficiently inhibited by designing ASO of a specific targeting lncRNA NEAT1 functional key domain, namely, a para-plaque assembly domain. Furthermore, ASO of a targeted mouse Neat1 homologous domain is subjected to intraocular injection, and laser-induced CNV focus formation can be remarkably inhibited in vivo. The invention provides a candidate drug for treating fundus neovascularization, which is independent of the traditional VEGF pathway and novel in action mechanism, and provides a new solution for patients who are insensitive to anti-VEGF therapy or need long-acting treatment.
Owner:JIANGNAN UNIV

A CTO patient-side collateral circulation biomarker MIA3 and application thereof

This invention provides a biomarker for collateral circulation in CTO patients, MIA3, and its application, belonging to the field of biotechnology. This invention reveals and verifies a significant positive correlation between plasma MIA3 levels and the quality of collateral circulation formation in CTO patients, and its predictive efficacy for good collateral circulation is superior to that of the known key angiogenesis factor VEGFA. This allows MIA3 to serve as a high-value, minimally invasive molecular marker for early, non-invasive identification of a patient's collateral circulation formation potential before interventional surgery, thereby enabling risk stratification and providing an objective basis for individualized treatment decisions (such as whether more aggressive intervention is needed). This invention clarifies that MIA3 is a key link in regulating collateral angiogenesis; by targeting and upregulating MIA3 activity, collateral angiogenesis and maturation in ischemic areas can be precisely promoted, providing a novel non-pharmacological, non-surgical treatment strategy for CTO patients.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

Nucleic acid molecule and pharmaceutical composition for treatment of peripheral arterial disease in lower limb, and use thereof

PCT designated stageWO2025208818A1Peptide/protein ingredientsArtificial cell constructsDiseaseAngiogenesis Factor
Provided are a nucleic acid molecule encoding a plurality of angiogenesis factors and a pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb, and use thereof. Relative to the prior art, the pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb can significantly promote lower limb angiogenesis and improve lower limb ischemia.
Owner:PROXYBIO THERAPEUTICS CO LTD

Traditional Chinese medicine composition for treating diabetic lower limb blood vessel ischemia as well as preparation method and application of traditional Chinese medicine composition

The invention discloses a traditional Chinese medicine composition for treating diabetic lower limb vascular ischemia as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following sixteen raw material medicines according to a specific weight ratio: radix aucklandiae, pericarpium citri reticulatae, rhizoma cyperi, fructus aurantii, folium perillae, herba schizonepetae, radix saposhnikoviae, rhizoma seu radix notopterygii, radix angelicae pubescentis, radix gentianae macrophyllae, ramulus mori, loofah sponge, radix angelicae sinensis, rhizoma chuanxiong, cassia The traditional Chinese medicine composition can be prepared into various oral preparations, and the preparation method comprises the steps of crushing, extracting, filtering, concentrating and the like. Pharmacodynamic experiments show that the traditional Chinese medicine composition can significantly improve expression of angiogenesis factors, improve blood perfusion of lower limbs, promote angiogenesis and effectively treat diabetic lower limb blood vessel ischemia and symptoms such as limb numbness, pain and ulcer caused by diabetic lower limb blood vessel ischemia, and has the advantages of being definite in curative effect, high in safety and low in cost.
Owner:THE SECOND AFFILIATED HOSPITAL OF TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

A method for assessing the risk of pregnancy outcome of pregnant women based on multi-factor feature analysis

This invention relates to the field of medical data analysis, and more particularly to a method for assessing the risk of pregnancy outcomes in pregnant women based on multifactor feature analysis. The method includes: acquiring individual measured time-series datasets and baseline reference data for physiological expectations; obtaining a gestational age-specific pathological surge penalty factor by weighting the ratio of angiogenic factors to anti-angiogenic factors; obtaining a cross-system pathological cascade time coupling factor by temporally tracing and coupling abnormal deviations in vascular system indicators and blood system indicators; obtaining a fused feature vector by correcting and fusing the initial linear regression slope features; and obtaining the pregnancy outcome risk assessment result by performing machine learning prediction on the fused feature vector. This method solves the problem that existing prediction methods based on linear regression slope extraction and feature splicing cannot effectively identify gestational age-specific early high-risk signals and cross-system short-term pathological cascade signals.
Owner:JILIN UNIVERSITY

Combination treatment for eye fibrosis and / or angiogenesis

PendingUS20250326832A1Senses disorderAntibody mimetics/scaffoldsAntagonismAngiogenesis Factor
Methods for the diagnosis, treatment and prophylaxis of fibrosis and / or angiogenesis, in particular in the eye, are disclosed. In particular embodiments, the methods employ antagonism of IL-11 mediated signalling and antagonism of angiogenesis. Also provided are combinations comprising an antagonist of IL-11 mediated signalling and an antagonist of an angiogenic factor.
Owner:BOEHRINGER INGELHEIM INT GMBH

Hydrogel system as well as preparation method and application thereof

ActiveCN120000580AOrganic active ingredientsMetabolism disorderDiseasePancreatic islet transplantation
The invention provides a hydrogel system as well as a preparation method and application thereof. The hydrogel system provided by the invention comprises oxidized hyaluronic acid, chitosan, perfluorotributylamine and an angiogenesis factor, and can provide oxygen for islet cells, promote in-situ islet blood vessel reconstruction, inhibit islet cell apoptosis and promote insulin secretion, so that the insulin secretion can be inhibited, and the pancreas islet cells can be inhibited. And a new strategy is provided for treatment of diseases caused by pancreas islet transplantation and even insulin deficiency or insufficiency.
Owner:GUANGZHOU MEDICAL UNIV

Application of TGF-β / Smad signaling pathway in treatment of corneal neovascularization in corneal alkali burn

The application belongs to the field of biological medicine, and provides application of TGF-beta / Smad signal pathway in treatment of corneal neovascularization after corneal alkali burn. The application proves that by inhibiting the TGF-beta / Smad signal pathway, the alkali burn-induced corneal neovascularization can be significantly reduced, and the corneal pathological damage is improved, and the mechanism of action involves regulating M2 type macrophage polarization and inhibiting the process of cellular ferroptosis of corneal tissue. It is found that by using a specific inhibitor SB-431542, the expression of TGF-beta1 and p-Smad2 / 3 proteins can be effectively reduced, the angiogenic factors such as VEGFA and CD31 are reduced, the inflammatory factors such as IL-4 and IL-10 are down-regulated, the GSH level is restored, and the Fe 2+ and MDA contents are reduced. The application is suitable for developing a targeted therapeutic drug for pathological neovascularization after corneal alkali burn, and provides a theoretical basis.
Owner:JINCHENG HOSPITAL

Preparation method and application of VEGF engineered endothelial extracellular vesicle

The invention discloses a preparation method and application of VEGF (vascular endothelial growth factor) engineered endothelial extracellular vesicles. The invention provides a specific preparation method, VEGF engineered endothelial extracellular vesicles (vEVs) and pharmaceutical application of the VEGF engineered endothelial extracellular vesicles. Compared with untreated common endothelial extracellular vesicles (EVs), the yield of the vEVs prepared by the invention is higher, and the vEVs are rich in higher-level angiogenesis promoting factors such as VEGF (vascular endothelial growth factor) and the like, show remarkably enhanced endothelial cell migration and tube formation promoting capability and accelerate endothelial cell uptake efficiency. The invention can be used for preparing medicines for promoting tissue repair and revascularization, and particularly has wide application prospects in the fields of diabetes wound healing, ischemic disease treatment and the like.
Owner:NANKAI UNIV

Microneedle patch for myocardial infarction treatment and preparation method thereof

The invention relates to a microneedle patch for treating myocardial infarction and a preparation method thereof. The microneedle patch and the needle tip are formed by curing a hydrogel solution I, and the hydrogel solution I contains methacrylated glucan, safflower polysaccharide and an angiogenesis factor mimic peptide; the substrate comprises an adhesion layer and an anti-fouling layer, and the adhesion layer is formed by curing a hydrogel solution II of which the main component is methylacryloyl glycine; and the anti-fouling layer is formed by curing a hydrogel solution III of which the main component is polyethylene glycol diacrylate. The microneedle patch provided by the invention not only can provide mechanical support for injured tissues and effectively ensure the delivery depth of drugs, but also can be well adhered to the surfaces of the tissues, and meanwhile, the microneedle patch is prevented from being adhered to other tissues and organs in an in-vivo environment. And the angiogenesis factor mimic peptide can promote the SPS to play an antioxidant role, so that a better myocardial repair effect can be achieved.
Owner:BEOGENE BIOTECH GUANGZHOU

Anti-angiogenesis composition containing sepsis acid A isolated from Prunella vulgaris as an active ingredient

ActiveCN113975283BEnhanced inhibitory effectExcellent growth inhibition effectOrganic active ingredientsSteroidsTube formationAngiogenesis Factor
The present invention relates to an anti-angiogenesis composition comprising sepsis A isolated from Prunella vulgaris as an active ingredient. The composition of the present invention has an excellent angiogenesis inhibitory effect as confirmed by cell invasion reduction effect, tube formation inhibitory effect, angiogenesis reduction in an in vivo angiogenesis model, and hemoglobin reduction effect.
Owner:NAT INST FOR KOREAN MEDICINE DEV +1